Senti Biosciences, Inc. (SNTI.US) opened more than 7% higher on Tuesday, trading at $2.54. The surge follows the company's updated Phase 1 SENTI-202 trial data for relapsed/refractory acute myeloid leukemia (R/R AML), demonstrating a 50% overall response rate (ORR) and 42% complete remission/partial hematologic recovery (CR/CRh). Notably, most responses were minimal residual disease-negative (MRD-Negative) with durable effects. The trial has also received Regenerative Medicine Advanced Therapy (RMAT) designation to advance into pivotal studies.